Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
7
×
national blog main
new york blog main
7
×
boston blog main
boston top stories
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
fda
national top stories
biotech
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
national
biontech
boston
bristol-myers squibb
cancer
deals
drugs
immunotherapy
loxo oncology
m&a
merck
What
time
7
×
fda
approved
bio
cancer
days
drug
friday
medicine
new
rna
second
acutus
adds
agency
ago
aimmune
airport
allergy
alliance
alnylam
annual
apocalypse
approval
approve
awaits
awarded
beds
bets
biological
bristol
buy
calls
celgene
changing
color
comes
companies
company
crispr
Language
unset
Current search:
time
×
" life sciences "
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Acutus, Maker of Next-Gen Electrophysiology Tech, Adds $100M Series D
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines